Multidisciplinary approach for patients with esophageal cancer

Table 2 Randomized trials of peri-operative chemotherapy in gastric and esophageal cancer

Ref.	Histology	Regimen	n	Resection	pCR	5-yr survival %	P value	Median survival (mo)
Kelson et al[23]	SCC (45%)	S	227	59%	NA	23 (3 yr)	NS	16.1
	AC (55%)	CF→S→CF	213	62%	2.50%	26 (3 yr)		14.9
Cunningham et al[22]	AC - Gastric	S	253	66%	NA	23	0.009	20
	25% GEJ	ECF→S→ECF	250	69%	0%	36		24
MRC et al[24]	SCC (35%)	S	402	54%	NA	17	0.004	13.3
	AC (65%)	CF→S	400	62%	NA	23		16.8
Roth et al[25]	AC/SCC	S	20	NR	NR	5	NS	9
		BVC→S	19			25		9
Ychou et al[26]	AC
	75% GEJ	S	111	111	NA	24	0.02	NR
	25% Gastric	CF→S→(CF)	113	113	NR	38		NR

CF: Cisplatin and 5-fluorouracil; SCC: Squamous cell carcinoma; ECF: Epirubicin, cisplatin and 5-fluorouracil; AC: Adenocarcinoma; NA: Not Applicable; GEF: Gastroesphageal junction/distal esophagus; NR: Not recorded; NS: Not significant; S: Surgery; BVC: Bleomycin, vindesine, cisplatin; pCR: Protein catabolic rate; GEJ: Gastroesophageal junction.